Oncology News

The addition of bemarituzumab to modified FOLFOX6 benefited patients with advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression, according to data presented at Gastrointestinal Cancers Symposium.

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.

Young adult survivors of colorectal cancer exhibited low overall health-related quality of life scores, with longer-term survivors reporting worse social and functional well-being than those diagnosed more recently.

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

The combination of panitumumab, ipilimumab and nivolumab induced responses among patients with metastatic colorectal cancer, according to phase 2 study results presented at Gastrointestinal Cancers Symposium.

The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with gastric or gastroesophageal adenocarcinoma.

A noninvasive multimodal blood test demonstrated high sensitivity and specificity for the detection of colorectal advanced neoplasia, according to prospective study results presented at Gastrointestinal Cancers Symposium.

The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients with gastric cancer and peritoneal metastases, according to study results presented at Gastrointestinal Cancers Symposium.

Patients with inflammatory bowel disease who either currently or formerly smoked cigarettes were at higher risk for colorectal neoplasia, according to study results.

Capsule endoscopy was comparable or superior to CT colonography as a colorectal neoplasia screening test, according to research published in Gut.